Pegah Larki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pegah Larki has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Chris Young
Leicester Institute of Pharmaceutical & Health Innovation, Faculty of Health & Life Sciences, De Montfort University, Leicester LE1 9BH, UK
1 shared publication - Ehsan Gharib
Département de chimie et biochimie, Université de Moncton, Moncton, NB E1A 3E9, Canada
1 shared publication - Ehsan Nazemalhosseini-Mojarad
Gastroenterology and Liver Diseases Research center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication - Fakhrosadat Anaraki
Colorectal Division of Surgical Ward, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication - Hamid Asadzadeh Aghdaei
Gastroenterology and Liver Diseases Research center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences
1 shared publication - James McClellan
School of Biological Sciences, University of Portsmouth, Portsmouth PO1 2UP, UK
1 shared publication
Latest Publications
- Open Access
- 2 March 2018
- Published by MDPI AG in Biomedicines
- Vol. 6 (1) , 27
The Application of Gene Expression Profiling in Predictions of Occult Lymph Node Metastasis in Colorectal Cancer Patients
A key factor in determining the likely outcome for a patient with colorectal cancer is whether or not the tumour has metastasised to the lymph nodes—information which is also important in assessing any possibilities of lymph node resection so as to improve survival. In this review we perform a wide-range assessment of literature relating to recent developments in gene expression profiling (GEP) of the primary tumour, to determine their utility in assessing node status. A set of characteristic genes seems to be involved in the prediction of lymph node metastasis (LNM) in colorectal patients. Hence, GEP is applicable in personalised/individualised/tailored therapies and provides insights into developing novel therapeutic targets. Not only is GEP useful in prediction of LNM, but it also allows classification based on differences such as sample size, target gene expression, and examination method.
- 2 March 2018
- Published by MDPI AG in Biomedicines
- Vol. 6 (1) , 27
Open AccessThe Application of Gene Expression Profiling in Predictions of Occult Lymph Node Metastasis in Colorectal Cancer Patients
A key factor in determining the likely outcome for a patient with colorectal cancer is whether or not the tumour has metastasised to the lymph nodes—information which is also important in assessing any possibilities of lymph node resection so as to improve survival. In this review we perform a wide-range assessment of literature relating to recent developments in gene expression profiling (GEP) of the primary tumour, to determine their utility in assessing node status. A set of characteristic genes seems to be involved in the prediction of lymph node metastasis (LNM) in colorectal patients. Hence, GEP is applicable in personalised/individualised/tailored therapies and provides insights into developing novel therapeutic targets. Not only is GEP useful in prediction of LNM, but it also allows classification based on differences such as sample size, target gene expression, and examination method.